Antiangiogenic combination therapy for the treatment of cancer
申请人:——
公开号:US20020103141A1
公开(公告)日:2002-08-01
The present invention provides combinations of a DNA topoisomerase I inhibiting agent and a selective COX-2 inhibiting agent for preventing, treating, and/or reducing the risk of developing a neoplasia disorder in a mammal.
Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.
NOVEL CONCOMITANT USE OF SULFONAMIDE COMPOUND WITH ANTI-CANCER AGENT
申请人:Eisai R&D Management Co., Ltd.
公开号:EP1859797A1
公开(公告)日:2007-11-28
The present invention relates to a pharmaceutical composition, a kit, a method of treating cancer and/or a method of inhibiting angiogenesis comprising a sulfonamide compound in combination with a platinum complex, a DNA-topoisomerase I inhibitor, an antimetabolite, a microtubule inhibitor or an antibiotic.
本发明涉及一种药物组合物、一种试剂盒、一种治疗癌症的方法和/或一种抑制血管生成的方法,其中包括磺酰胺化合物与铂复合物、DNA-拓扑异构酶 I 抑制剂、抗代谢药、微管抑制剂或抗生素的组合。
Implantable sensors and implantable pumps and anti-scarring agents
申请人:Hunter L. William
公开号:US20050152946A1
公开(公告)日:2005-07-14
Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.
Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.